Structure Therapeutics Reports 16.2% Mean Weight Loss at 72 Weeks With Oral Aleniglipron in ACCESS OLE Plus First-in-Human Data for ACCG-2671 Oral Amylin/Calcitonin Dual Agonist
Structure Therapeutics (NASDAQ: GPCR) reported Tuesday September 8, 2026 positive data across two lead oral small-molecule obesity programs. Aleniglipron (oral small-molecule GLP-1 receptor agonist, formerly GSBR-1290) reached mean 16.2% body weight loss at 72 weeks at the 180 mg dose in the ACCESS Phase 2b open-label extension (11.6% at 45 mg, 14.4% at 90 mg), with no observed weight-loss plateau; fewer than 5% of participants discontinued for adverse events using the improved 2.5 mg starting dose with four-week titration. The Phase 3 ACCOMPLISH program enrolls up to 3,600 adults with obesity plus comorbidity (ACCOMPLISH-1) and up to 1,100 with obesity plus type 2 diabetes (ACCOMPLISH-2), with topline expected H2 2028. Separately, ACCG-2671 (oral small-molecule dual amylin and calcitonin receptor agonist) posted first-in-human Phase 1/2a single-ascending-dose data in 31 healthy volunteers: 3.3% body weight reduction after a single 10 mg dose at Day 24, ~6-day half-life supporting once-weekly dosing, CTX-1 bone resorption biomarker reduction ~60% by Day 2, no serious adverse events, no drug-induced liver injury, no nausea or vomiting at 1-2 mg doses (dose-related GI effects at 5+ mg). A 12-week multiple-ascending-dose trial in obese participants is enrolling with topline expected H1 2027. Despite the data, GPCR shares fell in Tuesday trading on incumbent-class competitive concerns.